Entrada Committee Recommends Cohort 3 at 18 mg/kg in ELEVATE-44-201

An independent safety data monitoring committee recommended initiating Cohort 3 at the study’s top dose of 18 mg/kg. The company expects Cohort 1 open-label data by year-end 2026 and says Cohort 2 enrollment is complete, with data expected in Q1 2027.